Leuprolide

Background

Leuprolide (also spelled leuprorelin) is a synthetic gonadotropin-releasing hormone (GnRH) agonist used as a suppressive endocrine therapy across several hormone-sensitive conditions. It was developed as a long-acting analogue of native GnRH after the hormone’s hypothalamic-pituitary role was clarified, and it entered clinical development as one of the first GnRH agonists following discovery of GnRH [1]. A detailed review of its depot development notes that leuprolide acetate was the first GnRH agonist to progress into clinical use and that multiple depot formulations were later engineered to extend duration of action from 1 to 6 months [1].

The drug is marketed in the United States under the brand name Lupron and related depot products; the literature and regulatory landscape often refer specifically to the acetate salt and to formulation variants rather than to a single product. In clinical practice, leuprolide has been used primarily for prostate cancer, endometriosis, uterine fibroids, central precocious puberty (CPP), and several off-label or investigational endocrine and neurologic indications [1][2].

Mechanism of action

Leuprolide is an GnRH receptor agonist that binds GnRH receptors on anterior pituitary gonadotrophs [1][2]. Because it is administered continuously rather than in physiologic pulses, it initially stimulates luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, producing a short-lived flare in downstream sex steroid production, followed by receptor desensitization and downregulation with suppression of gonadotropins and sex steroids [1][2]. In men, this reduces testicular testosterone production; in women, it suppresses ovarian estrogen production; in children with CPP, it suppresses pubertal activation of the hypothalamic-pituitary-gonadal axis [1][3].

The clinical review of depot development emphasizes that leuprolide’s suppressive effect depends on formulation-driven sustained exposure and that microsphere systems based on biodegradable poly(lactic-co-glycolic acid) or poly(lactic acid) were central to extending duration of action [1]. The biologic effect is therefore a combination of peptide receptor agonism and pharmacokinetic engineering.

Evidence summary

The evidence base is strongest for prostate cancer and CPP, with substantial historical experience in endometriosis and fibroid-related bleeding control [1][3][4].

In advanced hormone-dependent prostate cancer, multiple therapeutic studies of long-acting leuprolide formulations demonstrated testosterone suppression to castrate levels and reductions in prostate-specific antigen (PSA), supporting non-inferiority of newer depot systems versus earlier reference products [1]. A separate development report on related leuprorelin implants described randomized and single-arm studies in men with advanced prostate cancer, likewise showing effective testosterone suppression and PSA normalization with comparable safety across formulations [3].

For central precocious puberty, a phase 3 multicenter open-label single-arm study evaluated 45 mg subcutaneous 6-month leuprolide acetate in 64 GnRH-agonist-naïve children at 25 sites in 6 countries; 59 completed the study, and the formulation demonstrated efficacy, pharmacokinetic adequacy, and safety sufficient to support approval [4]. The same report notes this product had recently been approved in the United States for CPP [4].

Leuprolide has also been investigated in neurologic disease. The LUCINDA trial was designed as a 52-week randomized placebo-controlled study of leuprolide plus cholinesterase inhibition in Alzheimer’s disease, reflecting the hypothesis that ovarian/testicular hormonal suppression might influence disease trajectory; however, this literature mainly reflects rationale and trial design rather than established efficacy, and the evidence remains limited and exploratory [2].

Overall, the most cited preclinical and translational literature supports the expected endocrine mechanism and formulation science, while the most clinically mature evidence supports sex steroid suppression and disease control in approved indications [1][2][4].

Clinical and research uses

Approved uses differ by jurisdiction and formulation, but the main established indications include advanced prostate cancer, central precocious puberty, endometriosis, and uterine fibroids (including preoperative anemia reduction in some formulations/contexts) [1][4]. Leuprolide is also used in assisted reproductive technology protocols in some regions and in other suppression-based endocrine applications, depending on formulation and label [1].

Investigational or off-label uses have included Alzheimer’s disease and other neurologic or psychiatric hypotheses involving gonadal axis suppression, although these remain unproven and are not standard of care [2]. The literature also describes formulation innovation, including small-volume subcutaneous depots and longer-acting microspheres, with the goal of improving convenience and adherence [1][4].

Dosing context

Reported dosing is indication- and formulation-specific and should not be interpreted as prescribing advice. The literature describes multiple depot strengths and intervals, including monthly, 3-month, 4-month, and 6-month regimens [1][4]. In CPP, the phase 3 study evaluated 45 mg subcutaneous every 6 months [4]. In prostate cancer and other suppressive indications, literature commonly reports depot regimens given at monthly or longer intervals, with product selection guided by desired duration of suppression and regulatory label [1][3].

Safety profile

Common adverse effects reflect hypogonadism and include hot flushes, decreased libido, erectile dysfunction, mood changes, headache, injection-site reactions, fatigue, and potential bone mineral density loss with prolonged use [1][2]. In children treated for CPP, adverse events in the phase 3 study were consistent with the known class profile and no new major safety signal was highlighted in the report [4].

A clinically important early effect is tumor flare or symptom flare during initial exposure, especially in prostate cancer, due to transient LH/FSH stimulation before downregulation [1][2]. Other concerns include vasomotor symptoms, metabolic changes, and loss of bone density with long-term suppression [1][2].

Contraindications and major precautions depend on the specific product label, but leuprolide is generally avoided in patients with known hypersensitivity to GnRH, GnRH agonists, or formulation excipients, and in those where transient flare could be dangerous without appropriate co-management [1]. Because the class causes profound sex steroid suppression, pregnancy is a major contraindication/precaution for many labeled uses, and pregnancy should be excluded when relevant [1]. In pediatric use, monitoring for growth velocity, pubertal suppression, and bone health is standard [4].

Regulatory status

In the United States, leuprolide acetate is an established, FDA-approved therapy with multiple formulations covering several indications; the 6-month subcutaneous formulation for central precocious puberty is specifically noted as recently approved in the phase 3 publication [4]. The broader depot development review confirms availability of several long-acting formulations in the United States [1].

In the European Union, leuprolide/leuprorelin products have also been authorized, but approval status is product- and country-specific rather than uniform across all formulations. The literature confirms that long-acting leuprolide/leuprorelin depot products are available globally, including in Europe, but exact current EU marketing authorization should be verified against the specific formulation and national label [1][3].